Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy

[1]  G. Gibney,et al.  Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. , 2023, Journal of Clinical Oncology.

[2]  Shubiao Zhang,et al.  Development and applications of mRNA treatment based on lipid nanoparticles. , 2023, Biotechnology advances.

[3]  C. Hsiao,et al.  mRNA delivery of dimeric human IgA protects mucosal tissues from bacterial infection , 2023, bioRxiv.

[4]  Yihai Cao,et al.  The landscape of mRNA nanomedicine , 2022, Nature Medicine.

[5]  Md Abu Sufian,et al.  Lipid-based nucleic acid therapeutics with in vivo efficacy. , 2022, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[6]  Jinzhong Lin,et al.  A Single Dose of Anti-HBsAg Antibody-Encoding mRNA-LNPs Suppressed HBsAg Expression: a Potential Cure of Chronic Hepatitis B Virus Infection , 2022, mBio.

[7]  Na Kong,et al.  Emerging mRNA technologies: delivery strategies and biomedical applications. , 2022, Chemical Society reviews.

[8]  A. Kore,et al.  Recent Advances in Modified Cap Analogs: Synthesis, Biochemical Properties, and mRNA Based Vaccines , 2022, Chemical record.

[9]  G. Calin,et al.  Targeting non-coding RNAs to overcome cancer therapy resistance , 2022, Signal Transduction and Targeted Therapy.

[10]  A. Keller,et al.  Emerging concepts of miRNA therapeutics: from cells to clinic. , 2022, Trends in genetics : TIG.

[11]  Xia Zhong,et al.  Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters , 2022, Cell Research.

[12]  U. Şahin,et al.  Ribozyme Assays to Quantify the Capping Efficiency of In Vitro-Transcribed mRNA , 2022, Pharmaceutics.

[13]  Zhengxin Cai,et al.  Intravenous Delivery of RNA Encoding Anti-PD-1 Human Monoclonal Antibody for Treating Intestinal Cancer , 2022, Journal of Cancer.

[14]  Bingbing Yu,et al.  Psychrophilic phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA byproducts in in vitro transcription , 2022, RNA biology.

[15]  Qiang Cheng,et al.  On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles , 2021, Proceedings of the National Academy of Sciences.

[16]  J. Lecerf,et al.  A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus , 2021, Nature Medicine.

[17]  C. E. Escobar Liquitay,et al.  Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. , 2021, The Cochrane database of systematic reviews.

[18]  Chenglin Deng,et al.  Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice , 2021, Signal Transduction and Targeted Therapy.

[19]  X. Mu,et al.  Immunogenicity of In Vitro-Transcribed RNA. , 2021, Accounts of chemical research.

[20]  Jie Deng,et al.  The nano delivery systems and applications of mRNA , 2021, European Journal of Medicinal Chemistry.

[21]  L. Álvarez-Vallina,et al.  Engineered mRNA and the Rise of Next-Generation Antibodies , 2021, Antibodies.

[22]  Liping Huang,et al.  Corrigendum: Development and Delivery Systems of mRNA Vaccines , 2021, Frontiers in Bioengineering and Biotechnology.

[23]  Philip L. Tzou,et al.  The biological and clinical significance of emerging SARS-CoV-2 variants , 2021, Nature Reviews Genetics.

[24]  Z. Rao,et al.  Structural biology of SARS-CoV-2 and implications for therapeutic development , 2021, Nature Reviews Microbiology.

[25]  Yunfeng Yan,et al.  mRNA delivery via non-viral carriers for biomedical applications. , 2021, International journal of pharmaceutics.

[26]  P. Giangrande,et al.  Advances in mRNA non-viral delivery approaches. , 2021, Advanced drug delivery reviews.

[27]  J. Tregoning,et al.  Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape , 2021, Nature reviews. Immunology.

[28]  T. Fiolet,et al.  Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.

[29]  A. Sieron,et al.  An Overview of Methods and Tools for Transfection of Eukaryotic Cells in vitro , 2021, Frontiers in Bioengineering and Biotechnology.

[30]  M. Seaman,et al.  Broadly Neutralizing Antibodies for HIV-1 Prevention , 2021, Frontiers in Immunology.

[31]  Q. Zhou,et al.  Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. , 2021, ACS nano.

[32]  Mengying Hu,et al.  mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver Malignancies , 2021, Advanced materials.

[33]  Ming Liu,et al.  Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies , 2021, Journal of Hematology & Oncology.

[34]  Irena Vlatkovic.  Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety , 2021, Biomedicines.

[35]  S. D. De Smedt,et al.  The dawn of mRNA vaccines: The COVID-19 case , 2021, Journal of Controlled Release.

[36]  Mary E. Haas,et al.  Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3 , 2021, Proceedings of the National Academy of Sciences.

[37]  Yvette N. Lamb.  BNT162b2 mRNA COVID-19 Vaccine: First Approval , 2021, Drugs.

[38]  Yuquan Wei,et al.  mRNA vaccine: a potential therapeutic strategy , 2021, Molecular Cancer.

[39]  Lukas Farbiak,et al.  Membrane destabilizing ionizable phospholipids for organ selective mRNA delivery and CRISPR/Cas gene editing , 2021, Nature Materials.

[40]  Rachel S. Riley,et al.  Ionizable lipid nanoparticles for in utero mRNA delivery , 2021, Science Advances.

[41]  Z. Rao,et al.  Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2 , 2020, National science review.

[42]  P. Dormitzer,et al.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.

[43]  N. Sonenberg,et al.  The multifaceted eukaryotic cap structure , 2020, Wiley interdisciplinary reviews. RNA.

[44]  Ting Zhang,et al.  Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.

[45]  S. Muyldermans.  Applications of Nanobodies. , 2020, Annual review of animal biosciences.

[46]  V. Thiel,et al.  Coronavirus biology and replication: implications for SARS-CoV-2 , 2020, Nature Reviews Microbiology.

[47]  Penghua Wang,et al.  Mechanisms of SARS-CoV-2 Transmission and Pathogenesis , 2020, Trends in Immunology.

[48]  S. Uchida,et al.  Nanomedicine-based approaches for mRNA delivery. , 2020, Molecular pharmaceutics.

[49]  S. Kang,et al.  From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.

[50]  Serge Muyldermans,et al.  A guide to: generation and design of nanobodies , 2020, The FEBS journal.

[51]  E. Calvo,et al.  Clinical Challenges of Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[52]  Mariana V. Ferreira,et al.  Progress and Perspectives in the Development of Lentiviral Vector Producer Cells , 2020, Biotechnology journal.

[53]  Larissa B. Thackray,et al.  Intramuscular Delivery of Replicon RNA Encoding ZIKV-117 Human Monoclonal Antibody Protects against Zika Virus Infection , 2020, Molecular therapy. Methods & clinical development.

[54]  William J. Liu,et al.  A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2 , 2020, Nature.

[55]  V. Hornung,et al.  Molecular mechanisms and cellular functions of cGAS–STING signalling , 2020, Nature Reviews Molecular Cell Biology.

[56]  C. Bachert,et al.  mRNA Encoding a Bispecific Single Domain Antibody Construct Protects against Influenza A Virus Infection in Mice , 2020, Molecular therapy. Nucleic acids.

[57]  E. Song,et al.  Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics , 2020, Cellular & Molecular Immunology.

[58]  P. Actis,et al.  Methods for protein delivery into cells: from current approaches to future perspectives. , 2020, Biochemical Society transactions.

[59]  D. Weissman,et al.  Recent advances in mRNA vaccine technology. , 2020, Current opinion in immunology.

[60]  Lijun Sun,et al.  Inhibition of cGAS-Mediated Interferon Response Facilitates Transgene Expression , 2020, iScience.

[61]  D. Weiner,et al.  In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies , 2020, BioDrugs.

[62]  S. Keam.  Trastuzumab Deruxtecan: First Approval , 2020, Drugs.

[63]  R. Aftab.  Coronavirus (COVID-19) , 2020, InnovAiT: Education and inspiration for general practice.

[64]  J. Pollard,et al.  Tumor-associated macrophages , 2020, Current Biology.

[65]  X. Jia,et al.  CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis , 2020, Molecular Cancer.

[66]  A. Rodríguez-Gascón,et al.  Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives , 2020, Nanomaterials.

[67]  L. Corey,et al.  Broadly Neutralizing Antibodies for HIV Prevention. , 2020, Annual review of medicine.

[68]  G. Tzertzinis,et al.  Synthesis of low immunogenicity RNA with high-temperature in vitro transcription , 2019, bioRxiv.

[69]  Y. Bang,et al.  HER2-targeted therapies — a role beyond breast cancer , 2019, Nature Reviews Clinical Oncology.

[70]  E. D. de Vries,et al.  A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. , 2019, Pharmacology & therapeutics.

[71]  S. Smedt,et al.  Three decades of messenger RNA vaccine development , 2019, Nano Today.

[72]  Daniel G. Anderson,et al.  mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[73]  R. Weiss,et al.  Nanobodies that Neutralize HIV , 2019, Vaccines.

[74]  Joan M. Block,et al.  A global scientific strategy to cure hepatitis B. , 2019, The lancet. Gastroenterology & hepatology.

[75]  V. Rotello,et al.  Protein Delivery into the Cell Cytosol using Non-Viral Nanocarriers , 2019, Theranostics.

[76]  James E. Crowe,et al.  A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection , 2019, Science Immunology.

[77]  Margaret A. Liu.  A Comparison of Plasmid DNA and mRNA as Vaccine Technologies , 2019, Vaccines.

[78]  T. Schlake,et al.  mRNA: A Novel Avenue to Antibody Therapy? , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[80]  U. Şahin,et al.  A Facile Method for the Removal of dsRNA Contaminant from In Vitro-Transcribed mRNA , 2019, Molecular therapy. Nucleic acids.

[81]  K. Roose,et al.  How mRNA therapeutics are entering the monoclonal antibody field , 2019, Journal of Translational Medicine.

[82]  J. McLellan,et al.  Respiratory syncytial virus entry and how to block it , 2019, Nature Reviews Microbiology.

[83]  J. Schellens,et al.  Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[84]  W. Merrick,et al.  Protein Synthesis Initiation in Eukaryotic Cells. , 2018, Cold Spring Harbor perspectives in biology.

[85]  W. Barclay,et al.  Host and viral determinants of influenza A virus species specificity , 2018, Nature Reviews Microbiology.

[86]  T. Schlake,et al.  mRNA as novel technology for passive immunotherapy , 2018, Cellular and Molecular Life Sciences.

[87]  Jonathan L. Kirschman,et al.  Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection , 2018, Nature Communications.

[88]  A. Thakur,et al.  Bispecific antibody based therapeutics: Strengths and challenges. , 2018, Blood reviews.

[89]  Leaf Huang,et al.  Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap , 2018, Nature Communications.

[90]  D. Weissman,et al.  Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses , 2018, The Journal of experimental medicine.

[91]  Mathumai Kanapathipillai,et al.  Treating p53 Mutant Aggregation-Associated Cancer , 2018, Cancers.

[92]  M. Milone,et al.  Clinical use of lentiviral vectors , 2018, Leukemia.

[93]  Katja Petzold,et al.  A guide to large-scale RNA sample preparation , 2018, Analytical and Bioanalytical Chemistry.

[94]  S. Whelan,et al.  STING-dependent translation inhibition restricts RNA virus replication , 2018, Proceedings of the National Academy of Sciences.

[95]  Lin Wang,et al.  Characterizing the dynamics underlying global spread of epidemics , 2018, Nature Communications.

[96]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[97]  Rhiju Das,et al.  Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them , 2017, Nature Reviews Molecular Cell Biology.

[98]  Correction to Lancet Glob Health 2017; 5: e1192–207 , 2017, The Lancet. Global health.

[99]  Marion C Lanteri,et al.  An update on Zika virus infection , 2017, The Lancet.

[100]  L. Morris,et al.  Prospects for passive immunity to prevent HIV infection , 2017, PLoS medicine.

[101]  D. Bailey,et al.  Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study. , 2017, The Lancet. Oncology.

[102]  Anice C. Lowen.  Constraints, Drivers, and Implications of Influenza A Virus Reassortment. , 2017, Annual review of virology.

[103]  N. Cheung,et al.  T cell engaging bispecific antibody (T‐BsAb): From technology to therapeutics , 2017, Pharmacology & therapeutics.

[104]  T. Schlake,et al.  mRNA mediates passive vaccination against infectious agents, toxins, and tumors , 2017, EMBO molecular medicine.

[105]  J. Utikal,et al.  Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer , 2017, Nature.

[106]  Tao Pan,et al.  Dynamic RNA Modifications in Gene Expression Regulation , 2017, Cell.

[107]  Özlem Türeci,et al.  Elimination of large tumors in mice by mRNA-encoded bispecific antibodies , 2017, Nature Medicine.

[108]  Penny A. Rudd,et al.  Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. , 2017, The Lancet. Infectious diseases.

[109]  D. Weissman,et al.  Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge , 2017, Nature Communications.

[110]  T. Dermody,et al.  Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies , 2017, The Journal of clinical investigation.

[111]  I. Verma,et al.  Systemic delivery of factor IX messenger RNA for protein replacement therapy , 2017, Proceedings of the National Academy of Sciences.

[112]  J. Schwarze,et al.  The Human Immune Response to Respiratory Syncytial Virus Infection , 2017, Clinical Microbiology Reviews.

[113]  M. Diamond,et al.  Zika Virus Pathogenesis and Tissue Tropism. , 2017, Cell host & microbe.

[114]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[115]  Emily B. Ehlerding,et al.  Preclinical Pharmacokinetics and Biodistribution Studies of 89Zr-Labeled Pembrolizumab , 2017, The Journal of Nuclear Medicine.

[116]  David J. Marchant,et al.  Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment , 2016, Clinical Microbiology Reviews.

[117]  Rong Ni,et al.  Virus-inspired nucleic acid delivery system: Linking virus and viral mimicry. , 2016, Advanced drug delivery reviews.

[118]  James E. Crowe,et al.  Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice , 2016, Nature.

[119]  George A. Calin,et al.  microRNA Therapeutics in Cancer — An Emerging Concept , 2016, EBioMedicine.

[120]  K. Kataoka,et al.  Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[121]  Olaide A. Odelola,et al.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. , 2016, The Cochrane database of systematic reviews.

[122]  G. B. Robb,et al.  mRNA capping: biological functions and applications , 2016, Nucleic acids research.

[123]  Meltem Avci-Adali,et al.  Concise Review: Application of In Vitro Transcribed Messenger RNA for Cellular Engineering and Reprogramming: Progress and Challenges , 2016, Stem cells.

[124]  Y. Wen,et al.  A human monoclonal antibody against small envelope protein of hepatitis B virus with potent neutralization effect , 2016, mAbs.

[125]  Mara Pereira Guerreiro,et al.  Trastuzumab in the Treatment of Breast Cancer , 2016, BioDrugs.

[126]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[127]  R. Weiss,et al.  N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[128]  P. Armand.  Immune checkpoint blockade in hematologic malignancies. , 2015, Blood.

[129]  S. Weaver,et al.  Chikungunya virus and the global spread of a mosquito-borne disease. , 2015, The New England journal of medicine.

[130]  D. Ecker,et al.  The therapeutic monoclonal antibody market , 2015, mAbs.

[131]  R. Poole.  Pembrolizumab: First Global Approval , 2014, Drugs.

[132]  Özlem Türeci,et al.  mRNA-based therapeutics — developing a new class of drugs , 2014, Nature Reviews Drug Discovery.

[133]  V. Rotello,et al.  Promises and Pitfalls of Intracellular Delivery of Proteins , 2014, Bioconjugate chemistry.

[134]  C. Coban,et al.  Innate Immune Signaling by, and Genetic Adjuvants for DNA Vaccination , 2013, Vaccines.

[135]  Serge Muyldermans,et al.  Nanobodies: natural single-domain antibodies. , 2013, Annual review of biochemistry.

[136]  Simon J. Henderson,et al.  Monoclonal antibody therapeutics: history and future. , 2012, Current opinion in pharmacology.

[137]  M. Nakanishi,et al.  Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine , 2012, Current gene therapy.

[138]  Hans A. Heus,et al.  Fast production of homogeneous recombinant RNA—towards large-scale production of RNA , 2012, Nucleic acids research.

[139]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[140]  M. Gale,et al.  Immune signaling by RIG-I-like receptors. , 2011, Immunity.

[141]  Nahum Sonenberg,et al.  Cap and cap‐binding proteins in the control of gene expression , 2011, Wiley interdisciplinary reviews. RNA.

[142]  J. Rosenecker,et al.  Expression of therapeutic proteins after delivery of chemically modified mRNA in mice , 2011, Nature Biotechnology.

[143]  Alexander Meissner,et al.  Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.

[144]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[145]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[146]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[147]  Houping Ni,et al.  Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. , 2005, Immunity.

[148]  D. Russell,et al.  Gene targeting with viral vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[149]  S. Akira,et al.  Species-Specific Recognition of Single-Stranded RNA via Toll-like Receptor 7 and 8 , 2004, Science.

[150]  Shizuo Akira,et al.  Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA , 2004, Science.

[151]  Zhi-zhen Wang.  [Central dogma of molecular biology]. , 2003, Sheng li ke xue jin zhan [Progress in physiology].

[152]  E. Gilboa,et al.  Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. , 2002, The Journal of clinical investigation.

[153]  R. Flavell,et al.  Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 , 2001, Nature.

[154]  S. Peltz,et al.  The cap-to-tail guide to mRNA turnover , 2001, Nature Reviews Molecular Cell Biology.

[155]  D. Curiel,et al.  Characterization of a messenger RNA polynucleotide vaccine vector. , 1995, Cancer research.

[156]  G. Lenzen,et al.  Induction of virus‐specific cytotoxic T lymphocytes in vivo by liposome‐entrapped mRNA , 1993, European journal of immunology.

[157]  F. Bloom,et al.  Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA. , 1992, Science.

[158]  G. Acsadi,et al.  Direct gene transfer into mouse muscle in vivo. , 1990, Science.

[159]  I. Verma,et al.  Cationic liposome-mediated RNA transfection. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[160]  D. Melton,et al.  Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. , 1984, Nucleic acids research.

[161]  G. J. Dimitriadis.  Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes , 1978, Nature.

[162]  R. E. Lockard,et al.  The synthesis of mouse hemoglobin beta-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA. , 1969, Biochemical and biophysical research communications.

[163]  R. A. Cox,et al.  Foreign nucleic acids as the stimulus to make interferon. , 1963, Lancet.

[164]  S. Brenner,et al.  An Unstable Intermediate Carrying Information from Genes to Ribosomes for Protein Synthesis , 1961, Nature.

[165]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[166]  A Mantalaris,et al.  The Increasingly Human and Profitable Monoclonal Antibody Market. , 2019, Trends in biotechnology.

[167]  L. R. Petersen,et al.  Zika Virus. , 2016, The New England journal of medicine.

[168]  Yu Yao,et al.  Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. , 2015, Trends in molecular medicine.

[169]  Peixuan Guo,et al.  Large scale purification of RNA nanoparticles by preparative ultracentrifugation. , 2015, Methods in molecular biology.

[170]  D. Weissman,et al.  HPLC purification of in vitro transcribed long RNA. , 2013, Methods in molecular biology.

[171]  Naomi A Mckoy,et al.  Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis. , 2013, The Cochrane database of systematic reviews.

[172]  V. Kaklamani,et al.  HER2-Positive Breast Cancer , 2012, Drugs.

[173]  W. Leader.  Pharmaceutical Biotechnology: Drug Discovery and Clinical Applications , 2004 .

[174]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..